The Discovery of CCR5 Receptor Antagonists for the Treatment of HIV Infection: Hit‐to‐Lead Studies

Duncan Armour(Pfizer (United Kingdom)), Anthony Wood(Pfizer (United Kingdom)), Blanda Stammen(Pfizer (United Kingdom)), David A. Price(University Hospital of Wales), Marcel J. de Groot(Pfizer (United Kingdom)), Manos Perros(Pfizer (United Kingdom)), Martin P. Edwards(Pfizer (United States))

ChemMedChem

June 6, 2006

10.1002/cmdc.200600031

Cited by 29

Related Papers

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

|Journal of Medicinal Chemistry|2011|924

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

|Journal of Medicinal Chemistry|2014|587

Using the Golden Triangle to optimize clearance and oral absorption

|Bioorganic & Medicinal Chemistry Letters|2009|382

Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry

|Nature Medicine|2006|368

Lipophilic Efficiency as an Important Metric in Drug Design

|Journal of Medicinal Chemistry|2018|340